JP2013516395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516395A5 JP2013516395A5 JP2012546418A JP2012546418A JP2013516395A5 JP 2013516395 A5 JP2013516395 A5 JP 2013516395A5 JP 2012546418 A JP2012546418 A JP 2012546418A JP 2012546418 A JP2012546418 A JP 2012546418A JP 2013516395 A5 JP2013516395 A5 JP 2013516395A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- alkylthio
- halogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 328
- 125000004414 alkyl thio group Chemical group 0.000 claims description 206
- 125000003545 alkoxy group Chemical group 0.000 claims description 182
- 229910052736 halogen Inorganic materials 0.000 claims description 80
- 150000002367 halogens Chemical class 0.000 claims description 80
- 125000003118 aryl group Chemical group 0.000 claims description 64
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 41
- -1 cyano, amino, aminocarbonyl Chemical group 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 150000004702 methyl esters Chemical class 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- GBXWORVXRWWDTA-UHFFFAOYSA-N 2,2-dichloroethyl 5-amino-3-[5-[(5-bromo-3-methylpyridine-2-carbonyl)amino]-2-fluorophenyl]-3-(difluoromethyl)-2,6-dihydropyrazine-1-carboxylate Chemical compound CC1=CC(Br)=CN=C1C(=O)NC1=CC=C(F)C(C2(N=C(N)CN(C2)C(=O)OCC(Cl)Cl)C(F)F)=C1 GBXWORVXRWWDTA-UHFFFAOYSA-N 0.000 claims 1
- NWYKTGFANHHXBN-UHFFFAOYSA-N 2-amino-n-[3-[5-amino-3-(difluoromethyl)-2,6-dihydro-1h-pyrazin-3-yl]-4-fluorophenyl]-6-oxo-1h-pyrazine-3-carboxamide Chemical compound C1NCC(N)=NC1(C(F)F)C1=CC(NC(=O)C2=C(NC(=O)C=N2)N)=CC=C1F NWYKTGFANHHXBN-UHFFFAOYSA-N 0.000 claims 1
- ZKNMXFGYYJETSC-UHFFFAOYSA-N 3-amino-n-[3-[5-amino-3-(difluoromethyl)-2,6-dihydro-1h-pyrazin-3-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound NC1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C(C2(N=C(N)CNC2)C(F)F)=C1 ZKNMXFGYYJETSC-UHFFFAOYSA-N 0.000 claims 1
- GSOCTKHBFREQCV-UHFFFAOYSA-N 5-bromo-3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC(Br)=CN=C1C(O)=O GSOCTKHBFREQCV-UHFFFAOYSA-N 0.000 claims 1
- HRLVPHGCEGTVLK-UHFFFAOYSA-N 5-cyanopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)C=N1 HRLVPHGCEGTVLK-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- FGPUURAPBZPKJF-UHFFFAOYSA-N n-[3-(3-amino-1,5-dimethyl-6-oxo-2h-pyrazin-5-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound O=C1N(C)CC(N)=NC1(C)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F FGPUURAPBZPKJF-UHFFFAOYSA-N 0.000 claims 1
- HJOOOXDRGOESCS-UHFFFAOYSA-N n-[3-(3-amino-1,5-dimethyl-6-oxo-2h-pyrazin-5-yl)phenyl]-5-bromopyridine-2-carboxamide Chemical compound O=C1N(C)CC(N)=NC1(C)C1=CC=CC(NC(=O)C=2N=CC(Br)=CC=2)=C1 HJOOOXDRGOESCS-UHFFFAOYSA-N 0.000 claims 1
- KDEOLGIEXQPNFC-UHFFFAOYSA-N n-[3-(3-amino-2-ethyl-1,5-dimethyl-6-oxo-2h-pyrazin-5-yl)phenyl]-5-bromopyridine-2-carboxamide Chemical compound N1=C(N)C(CC)N(C)C(=O)C1(C)C1=CC=CC(NC(=O)C=2N=CC(Br)=CC=2)=C1 KDEOLGIEXQPNFC-UHFFFAOYSA-N 0.000 claims 1
- FOLNCKZOMNIALC-UHFFFAOYSA-N n-[3-(5-amino-1,3-dimethyl-2,6-dihydropyrazin-3-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound C1N(C)CC(N)=NC1(C)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F FOLNCKZOMNIALC-UHFFFAOYSA-N 0.000 claims 1
- VYTHRSNJIFMUBH-UHFFFAOYSA-N n-[3-(5-amino-1,3-dimethyl-6-oxo-2h-pyrazin-3-yl)-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(C)CC1(C)C1=CC(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C1F VYTHRSNJIFMUBH-UHFFFAOYSA-N 0.000 claims 1
- VGTILVOMEOFBMU-UHFFFAOYSA-N n-[3-(5-amino-1,3-dimethyl-6-oxo-2h-pyrazin-3-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(C)CC1(C)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F VGTILVOMEOFBMU-UHFFFAOYSA-N 0.000 claims 1
- IBPGEEKFYIPLRV-UHFFFAOYSA-N n-[3-(5-amino-1,3-dimethyl-6-oxo-2h-pyrazin-3-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(C)CC1(C)C1=CC(NC(=O)C=2N=CC(Cl)=CC=2)=CC=C1F IBPGEEKFYIPLRV-UHFFFAOYSA-N 0.000 claims 1
- GMUSGOAHDMSZNC-UHFFFAOYSA-N n-[3-(5-amino-1-ethyl-3-methyl-6-oxo-2h-pyrazin-3-yl)-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(CC)CC1(C)C1=CC(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C1F GMUSGOAHDMSZNC-UHFFFAOYSA-N 0.000 claims 1
- NNONTILIEPOHQT-UHFFFAOYSA-N n-[3-(5-amino-1-ethyl-3-methyl-6-oxo-2h-pyrazin-3-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(CC)CC1(C)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F NNONTILIEPOHQT-UHFFFAOYSA-N 0.000 claims 1
- WFPDPMQFKZCRFF-UHFFFAOYSA-N n-[3-(5-amino-1-ethyl-3-methyl-6-oxo-2h-pyrazin-3-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(CC)CC1(C)C1=CC(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C1F WFPDPMQFKZCRFF-UHFFFAOYSA-N 0.000 claims 1
- IPEYSDUMVODEGM-UHFFFAOYSA-N n-[3-(5-amino-3-methyl-6-oxo-1-propan-2-yl-2h-pyrazin-3-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(C(C)C)CC1(C)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F IPEYSDUMVODEGM-UHFFFAOYSA-N 0.000 claims 1
- SGPKXKUDYCPOBE-UHFFFAOYSA-N n-[3-(5-amino-3-methyl-6-oxo-1-pyridin-3-yl-2h-pyrazin-3-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound O=C1C(N)=NC(C)(C=2C(=CC=C(NC(=O)C=3N=CC(Br)=CC=3)C=2)F)CN1C1=CC=CN=C1 SGPKXKUDYCPOBE-UHFFFAOYSA-N 0.000 claims 1
- YUOPBZQOSQHOJB-UHFFFAOYSA-N n-[3-[1-acetyl-5-amino-3-(difluoromethyl)-2,6-dihydropyrazin-3-yl]-4-fluorophenyl]-5-(difluoromethoxy)-3-methylpyridine-2-carboxamide Chemical compound C1N(C(=O)C)CC(N)=NC1(C(F)F)C1=CC(NC(=O)C=2C(=CC(OC(F)F)=CN=2)C)=CC=C1F YUOPBZQOSQHOJB-UHFFFAOYSA-N 0.000 claims 1
- JHDMJWNJCPZFBW-UHFFFAOYSA-N n-[3-[1-acetyl-5-amino-3-(difluoromethyl)-2,6-dihydropyrazin-3-yl]-4-fluorophenyl]-5-bromo-3-methylpyridine-2-carboxamide Chemical compound C1N(C(=O)C)CC(N)=NC1(C(F)F)C1=CC(NC(=O)C=2C(=CC(Br)=CN=2)C)=CC=C1F JHDMJWNJCPZFBW-UHFFFAOYSA-N 0.000 claims 1
- FOLBFWMABGBJIK-UHFFFAOYSA-N n-[3-[5-amino-1-(2-methoxyethyl)-3-methyl-6-oxo-2h-pyrazin-3-yl]-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(CCOC)CC1(C)C1=CC(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C1F FOLBFWMABGBJIK-UHFFFAOYSA-N 0.000 claims 1
- PZMNGGWMBNDIDP-UHFFFAOYSA-N n-[3-[5-amino-1-(2-methoxyethyl)-3-methyl-6-oxo-2h-pyrazin-3-yl]-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(CCOC)CC1(C)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F PZMNGGWMBNDIDP-UHFFFAOYSA-N 0.000 claims 1
- PBVWMRZIDFSIRJ-UHFFFAOYSA-N n-[3-[5-amino-1-(cyclopropanecarbonyl)-3-(difluoromethyl)-2,6-dihydropyrazin-3-yl]-4-fluorophenyl]-5-bromo-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Br)=CN=C1C(=O)NC1=CC=C(F)C(C2(N=C(N)CN(C2)C(=O)C2CC2)C(F)F)=C1 PBVWMRZIDFSIRJ-UHFFFAOYSA-N 0.000 claims 1
- GFKHOTKTQLRBEC-UHFFFAOYSA-N n-[3-[5-amino-3-(difluoromethyl)-1-(2-methoxyacetyl)-2,6-dihydropyrazin-3-yl]-4-fluorophenyl]-5-bromo-3-methylpyridine-2-carboxamide Chemical compound C1N(C(=O)COC)CC(N)=NC1(C(F)F)C1=CC(NC(=O)C=2C(=CC(Br)=CN=2)C)=CC=C1F GFKHOTKTQLRBEC-UHFFFAOYSA-N 0.000 claims 1
- ZKECAQPFRZAODT-UHFFFAOYSA-N n-[3-[5-amino-3-(difluoromethyl)-2,6-dihydro-1h-pyrazin-3-yl]-4-fluorophenyl]-5-(difluoromethoxy)-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(OC(F)F)=CN=C1C(=O)NC1=CC=C(F)C(C2(N=C(N)CNC2)C(F)F)=C1 ZKECAQPFRZAODT-UHFFFAOYSA-N 0.000 claims 1
- YIVQZDWEYRMEFX-UHFFFAOYSA-N n-[3-[5-amino-3-(difluoromethyl)-2,6-dihydro-1h-pyrazin-3-yl]-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound C1NCC(N)=NC1(C(F)F)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F YIVQZDWEYRMEFX-UHFFFAOYSA-N 0.000 claims 1
- UUBHPJXFLIBPAK-UHFFFAOYSA-N n-[3-[5-amino-3-(difluoromethyl)-2,6-dihydro-1h-pyrazin-3-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C1NCC(N)=NC1(C(F)F)C1=CC(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C1F UUBHPJXFLIBPAK-UHFFFAOYSA-N 0.000 claims 1
- QQJJZOBMLMQJSH-UHFFFAOYSA-N n-[3-[5-amino-3-methyl-1-(1-methylpyrazol-4-yl)-6-oxo-2h-pyrazin-3-yl]-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound C1=NN(C)C=C1N1C(=O)C(N)=NC(C)(C=2C(=CC=C(NC(=O)C=3N=CC(Br)=CC=3)C=2)F)C1 QQJJZOBMLMQJSH-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29172409P | 2009-12-31 | 2009-12-31 | |
| US61/291,724 | 2009-12-31 | ||
| PCT/EP2010/070502 WO2011080176A1 (en) | 2009-12-31 | 2010-12-22 | Pyrazine derivatives and their use in the treatment of neurological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516395A JP2013516395A (ja) | 2013-05-13 |
| JP2013516395A5 true JP2013516395A5 (enExample) | 2014-08-21 |
| JP5600754B2 JP5600754B2 (ja) | 2014-10-01 |
Family
ID=43598456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546418A Expired - Fee Related JP5600754B2 (ja) | 2009-12-31 | 2010-12-22 | ピラジン誘導体および神経障害の処置におけるそれらの使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20120277244A1 (enExample) |
| EP (1) | EP2519515B1 (enExample) |
| JP (1) | JP5600754B2 (enExample) |
| KR (1) | KR101419157B1 (enExample) |
| CN (1) | CN102712621B (enExample) |
| AU (1) | AU2010338365B2 (enExample) |
| BR (1) | BR112012015916A2 (enExample) |
| CA (1) | CA2785341A1 (enExample) |
| CL (1) | CL2012001762A1 (enExample) |
| CR (1) | CR20120332A (enExample) |
| CU (1) | CU20120099A7 (enExample) |
| EA (1) | EA201200952A1 (enExample) |
| EC (1) | ECSP12012065A (enExample) |
| ES (1) | ES2445536T3 (enExample) |
| GT (1) | GT201200219A (enExample) |
| HN (1) | HN2012001413A (enExample) |
| IL (1) | IL220268A0 (enExample) |
| MX (1) | MX2012007754A (enExample) |
| NZ (1) | NZ600136A (enExample) |
| PE (1) | PE20121640A1 (enExample) |
| PH (1) | PH12012501007A1 (enExample) |
| PL (1) | PL2519515T3 (enExample) |
| PT (1) | PT2519515E (enExample) |
| SG (1) | SG181431A1 (enExample) |
| TN (1) | TN2012000249A1 (enExample) |
| WO (1) | WO2011080176A1 (enExample) |
| ZA (1) | ZA201203614B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| AR081587A1 (es) | 2010-06-09 | 2012-10-03 | Janssen Pharmaceutica Nv | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) |
| EA201291366A1 (ru) * | 2010-06-09 | 2013-04-30 | Янссен Фармацевтика Нв | Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace) |
| SG186408A1 (en) * | 2010-06-28 | 2013-01-30 | Janssen Pharmaceutica Nv | 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| ES2648143T3 (es) | 2010-12-22 | 2017-12-28 | Janssen Pharmaceutica Nv | Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de la beta-secretasa (BACE) |
| US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
| KR101569260B1 (ko) | 2011-01-13 | 2015-11-13 | 노파르티스 아게 | 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도 |
| EA201391033A1 (ru) * | 2011-01-13 | 2014-01-30 | Новартис Аг | Ингибиторы bace-2 для лечения метаболических расстройств |
| US9346811B2 (en) | 2011-03-01 | 2016-05-24 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| JP5853035B2 (ja) | 2011-03-09 | 2016-02-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体 |
| EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| BR112013026341A2 (pt) | 2011-04-13 | 2019-09-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| RU2014111055A (ru) | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| CN104870000A (zh) | 2012-12-20 | 2015-08-26 | 默沙东公司 | 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途 |
| KR102243134B1 (ko) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체 |
| EP3008067B1 (en) | 2013-06-12 | 2017-03-29 | Janssen Pharmaceutica N.V. | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace) |
| BR112015030597A2 (pt) | 2013-06-12 | 2017-07-25 | Janssen Pharmaceutica Nv | derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace) |
| JP2017538753A (ja) | 2014-12-18 | 2017-12-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ２，３，４，５−テトラヒドロピリジン−６−アミンおよび３，４−ジヒドロ−２Ｈ−ピロール−５−アミンの化合物のβセクレターゼ阻害剤 |
| CN107011134B (zh) * | 2017-04-28 | 2021-02-05 | 浙江中欣氟材股份有限公司 | 一种2-氟-5-溴苯乙酮的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6911868A (enExample) | 1968-08-31 | 1970-03-03 | ||
| AUPQ319899A0 (en) * | 1999-10-01 | 1999-10-28 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds |
| WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7728025B2 (en) | 2003-12-29 | 2010-06-01 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted benzimidazole derivative |
| US20050215884A1 (en) * | 2004-02-27 | 2005-09-29 | Greicius Michael D | Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI |
| ES2537898T3 (es) * | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| PT2404919E (pt) * | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| EP2094682A2 (en) * | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| BRPI0906962B8 (pt) | 2008-01-18 | 2021-05-25 | Eisai R&D Man Co Ltd | composto de aminodiidrotiazina fundido |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| UY32799A (es) * | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| EA201291366A1 (ru) * | 2010-06-09 | 2013-04-30 | Янссен Фармацевтика Нв | Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace) |
| SG186408A1 (en) * | 2010-06-28 | 2013-01-30 | Janssen Pharmaceutica Nv | 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia |
-
2010
- 2010-12-22 US US13/518,907 patent/US20120277244A1/en not_active Abandoned
- 2010-12-22 EP EP20100796064 patent/EP2519515B1/en active Active
- 2010-12-22 PE PE2012000897A patent/PE20121640A1/es not_active Application Discontinuation
- 2010-12-22 JP JP2012546418A patent/JP5600754B2/ja not_active Expired - Fee Related
- 2010-12-22 PH PH1/2012/501007A patent/PH12012501007A1/en unknown
- 2010-12-22 ES ES10796064T patent/ES2445536T3/es active Active
- 2010-12-22 KR KR1020127019872A patent/KR101419157B1/ko not_active Expired - Fee Related
- 2010-12-22 BR BR112012015916A patent/BR112012015916A2/pt not_active IP Right Cessation
- 2010-12-22 NZ NZ60013610A patent/NZ600136A/xx not_active IP Right Cessation
- 2010-12-22 SG SG2012036935A patent/SG181431A1/en unknown
- 2010-12-22 PT PT10796064T patent/PT2519515E/pt unknown
- 2010-12-22 CA CA 2785341 patent/CA2785341A1/en not_active Abandoned
- 2010-12-22 MX MX2012007754A patent/MX2012007754A/es active IP Right Grant
- 2010-12-22 EA EA201200952A patent/EA201200952A1/ru unknown
- 2010-12-22 CN CN201080060047.7A patent/CN102712621B/zh not_active Expired - Fee Related
- 2010-12-22 WO PCT/EP2010/070502 patent/WO2011080176A1/en not_active Ceased
- 2010-12-22 AU AU2010338365A patent/AU2010338365B2/en not_active Ceased
- 2010-12-22 PL PL10796064T patent/PL2519515T3/pl unknown
-
2012
- 2012-05-17 ZA ZA2012/03614A patent/ZA201203614B/en unknown
- 2012-05-22 TN TNP2012000249A patent/TN2012000249A1/en unknown
- 2012-06-07 IL IL220268A patent/IL220268A0/en unknown
- 2012-06-19 CR CR20120332A patent/CR20120332A/es unknown
- 2012-06-25 CU CU20120099A patent/CU20120099A7/es unknown
- 2012-06-27 CL CL2012001762A patent/CL2012001762A1/es unknown
- 2012-06-28 HN HN2012001413A patent/HN2012001413A/es unknown
- 2012-06-28 GT GT201200219A patent/GT201200219A/es unknown
- 2012-07-25 EC ECSP12012065 patent/ECSP12012065A/es unknown
-
2015
- 2015-07-21 US US14/805,446 patent/US20150322038A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2454411C2 (ru) | Производные хинолина | |
| JP2011520792A5 (enExample) | ||
| RU2424240C2 (ru) | Антибактериальные производные пиперидина | |
| ES2536762T3 (es) | Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este | |
| ES2445536T3 (es) | Derivados de la pirazina y su uso en el tratamiento de trastornos neurológicos | |
| RU2013106755A (ru) | 1,4,5,6-тетрагидропиримидин-2-иламины | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| JP2011515398A5 (enExample) | ||
| HRP20130143T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| JP2012516871A5 (enExample) | ||
| RU2017144495A (ru) | Противогельминтные депсипептидные соединения | |
| JP2007519754A5 (enExample) | ||
| HRP20211255T1 (hr) | Derivati pirana kao inhibitori cyp11a1 (citokrom p450 monooksigenaze 11a1) | |
| RU2005110061A (ru) | Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло(2,2,1)гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина | |
| JP2020502229A5 (enExample) | ||
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| JP2011519374A5 (enExample) | ||
| JP2017523972A5 (enExample) | ||
| RU2011151277A (ru) | Мостиковые производные спиро[2.4]гептана в качестве агонистов рецептора alx и/или fprl2 | |
| AR082458A1 (es) | Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 | |
| JP2023512823A5 (enExample) | ||
| ZA200702435B (en) | PI3 Kinase gamma inhibitors for the treatment of anaemia | |
| RU2403253C2 (ru) | Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а | |
| JP2004525183A5 (enExample) | ||
| RU2008151755A (ru) | Ингибитор hsp90 |